Blue Earth Diagnostics, a Bracco company, will present new clinical data at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting from June 21-24, 2025, in New Orleans. Key discussions will focus on their PSMA-targeted PET agent and investigational use of 18F-fluciclovine for detecting multiple myeloma and in patients with negative PSMA scans. They will share seven abstracts on various PET imaging advancements and their applications. The company aims to enhance physician capabilities for better clinical decision-making through innovative imaging solutions.
Wed, 18 Jun 2025 12:00:00 GMT | PR Newswire